Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna Publishes Data on RNAi Technology in Cancer

Premium

Dicerna Pharmaceuticals this week announced the publication of data by company researchers and collaborators demonstrating the potential therapeutic benefit of knocking down a key cancer target using RNAi.

Appearing in Molecular Therapy, the paper shows that Dicerna's Dicer-substrate molecules, when devliered using its proprietary lipid nanoparticles, can significantly reduce the expression of beta-catenin in liver cancer models.

Further, treatment reduced animals' tumor burden, either alone or in combination with chemotherapy.

“These data provide important proof of concept for Dicerna’s approach … to silence traditionally undruggable cancer targets,” Dicerna CSO Bob Brown said in a statement.

Dicerna is currently preparing to begin clinical testing of a Dicer-substrate-based hepatocellular cancer treatment drug, which targets Myc, in 2014.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.